ArticleInternational journal of genomics2026
Establishment of a m
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Establishment of a mInternational journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To determine the prognosis of osteosarcoma, multiple predictive models have been constructed in recent years. Nevertheless, the model for N6-methyladenosine (m Methods: Gene expression matrices and clinical data were extracted from the GEO datasets GSE21257 and GSE16091. Randomly selected 70% of samples from GSE21257 were assigned as the training dataset, while the remaining 30% of samples from GSE21257 and all samples from GSE16091 were designated as the internal test and external test datasets, respectively. The predictive model was developed using elastic net-penalized Cox regression. Receiver operating characteristic (ROC) analysis, Kaplan-Meier analysis, and Wilcoxon's tests were conducted in the training, internal test, and external test datasets to validate its efficacy. Additionally, a clinical nomogram was established for prognostic prediction. The expression of several signature genes was verified in osteosarcoma cell lines and clinical samples. In vitro experiments were performed to elucidate the impact of signature genes on the osteosarcoma phenotype. Immune infiltration analysis and gene set enrichment analysis (GSEA) were further integrated to validate the ability of the risk model to discriminate cancer characteristics. Results: A total of 110 m Conclusions: A prognostic model based on m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.